Management of reactive arthritis in a juvenile gorilla (Gorilla gorilla gorilla) with long-term sulfasalazine therapy

Donald L. Neiffer, Bruce M. Rothschild, Steven K. Marks, Julie A. Urvater, David Watkins

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

A juvenile western lowland gorilla (Gorilla gorilla gorilla) experienced recurrent fever, lethargy, diarrhea, and/or arthritis starting at age 6 mo. During an episode at age 15 mo, Shigella sp. was isolated from diarrheic feces. At age 41 mo, reactive arthritis was diagnosed. In addition, the gorilla's growth was retarded. All arthritic attacks were managed symptomatically prior to age 4 yr, at which time a severe episode precipitated the implementation of therapy with sulfasalazine, an arthritis suppressive medication. Examination 27 mo later revealed cessation of progressive joint pathology although the animal exhibited decreased range of motion in most joints. The gorilla has been on sulfasalazine therapy for 4 yr without lameness. Growth has resumed, and there has been no radiographic evidence of progressive joint degeneration. Immunogenetic analysis of whole blood obtained at age 68 mo identified the gorilla major histocompatibility class I allele, Gogo-B*0101, which has limited nucleotide sequence similarity to HLA-B27, an allele associated with postinfection reactive arthritis in humans. Sulfasalazine therapy effectively managed reactive arthritis in this gorilla and should be considered for similarly frequently affected animals. Juvenile gorillas, in populations with a history of clinical shigellosis and/or postdiarrhea arthritis, may benefit from prophylactic sulfasalazine therapy after episodes of bacterial enterocolitis. Sulfasalazine therapy should be considered in all gorillas, juvenile and adult, experiencing confirmed Shigella sp.-associated enterocolitis.

Original languageEnglish
Pages (from-to)539-551
Number of pages13
JournalJournal of Zoo and Wildlife Medicine
Volume31
Issue number4
StatePublished - Dec 1 2000
Externally publishedYes

Fingerprint

Gorilla gorilla
Reactive Arthritis
Sulfasalazine
arthritis
Gorilla
therapeutics
Arthritis
enterocolitis
Shigella
allele
Enterocolitis
Therapeutics
Joints
animal
animal pathology
shigellosis
pathology
immunogenetics
alleles
feces

Keywords

  • Gorilla gorilla gorilla
  • Reactive arthritis
  • Spondyloarthropathy
  • Sulfasalazine
  • Western lowland gorilla

ASJC Scopus subject areas

  • Animal Science and Zoology
  • Environmental Science(all)
  • veterinary(all)

Cite this

Management of reactive arthritis in a juvenile gorilla (Gorilla gorilla gorilla) with long-term sulfasalazine therapy. / Neiffer, Donald L.; Rothschild, Bruce M.; Marks, Steven K.; Urvater, Julie A.; Watkins, David.

In: Journal of Zoo and Wildlife Medicine, Vol. 31, No. 4, 01.12.2000, p. 539-551.

Research output: Contribution to journalArticle

Neiffer, Donald L. ; Rothschild, Bruce M. ; Marks, Steven K. ; Urvater, Julie A. ; Watkins, David. / Management of reactive arthritis in a juvenile gorilla (Gorilla gorilla gorilla) with long-term sulfasalazine therapy. In: Journal of Zoo and Wildlife Medicine. 2000 ; Vol. 31, No. 4. pp. 539-551.
@article{182665d00dd24099b83e4a2ccf394342,
title = "Management of reactive arthritis in a juvenile gorilla (Gorilla gorilla gorilla) with long-term sulfasalazine therapy",
abstract = "A juvenile western lowland gorilla (Gorilla gorilla gorilla) experienced recurrent fever, lethargy, diarrhea, and/or arthritis starting at age 6 mo. During an episode at age 15 mo, Shigella sp. was isolated from diarrheic feces. At age 41 mo, reactive arthritis was diagnosed. In addition, the gorilla's growth was retarded. All arthritic attacks were managed symptomatically prior to age 4 yr, at which time a severe episode precipitated the implementation of therapy with sulfasalazine, an arthritis suppressive medication. Examination 27 mo later revealed cessation of progressive joint pathology although the animal exhibited decreased range of motion in most joints. The gorilla has been on sulfasalazine therapy for 4 yr without lameness. Growth has resumed, and there has been no radiographic evidence of progressive joint degeneration. Immunogenetic analysis of whole blood obtained at age 68 mo identified the gorilla major histocompatibility class I allele, Gogo-B*0101, which has limited nucleotide sequence similarity to HLA-B27, an allele associated with postinfection reactive arthritis in humans. Sulfasalazine therapy effectively managed reactive arthritis in this gorilla and should be considered for similarly frequently affected animals. Juvenile gorillas, in populations with a history of clinical shigellosis and/or postdiarrhea arthritis, may benefit from prophylactic sulfasalazine therapy after episodes of bacterial enterocolitis. Sulfasalazine therapy should be considered in all gorillas, juvenile and adult, experiencing confirmed Shigella sp.-associated enterocolitis.",
keywords = "Gorilla gorilla gorilla, Reactive arthritis, Spondyloarthropathy, Sulfasalazine, Western lowland gorilla",
author = "Neiffer, {Donald L.} and Rothschild, {Bruce M.} and Marks, {Steven K.} and Urvater, {Julie A.} and David Watkins",
year = "2000",
month = "12",
day = "1",
language = "English",
volume = "31",
pages = "539--551",
journal = "Journal of Zoo and Wildlife Medicine",
issn = "1042-7260",
publisher = "American Association of Zoo Veterinarians",
number = "4",

}

TY - JOUR

T1 - Management of reactive arthritis in a juvenile gorilla (Gorilla gorilla gorilla) with long-term sulfasalazine therapy

AU - Neiffer, Donald L.

AU - Rothschild, Bruce M.

AU - Marks, Steven K.

AU - Urvater, Julie A.

AU - Watkins, David

PY - 2000/12/1

Y1 - 2000/12/1

N2 - A juvenile western lowland gorilla (Gorilla gorilla gorilla) experienced recurrent fever, lethargy, diarrhea, and/or arthritis starting at age 6 mo. During an episode at age 15 mo, Shigella sp. was isolated from diarrheic feces. At age 41 mo, reactive arthritis was diagnosed. In addition, the gorilla's growth was retarded. All arthritic attacks were managed symptomatically prior to age 4 yr, at which time a severe episode precipitated the implementation of therapy with sulfasalazine, an arthritis suppressive medication. Examination 27 mo later revealed cessation of progressive joint pathology although the animal exhibited decreased range of motion in most joints. The gorilla has been on sulfasalazine therapy for 4 yr without lameness. Growth has resumed, and there has been no radiographic evidence of progressive joint degeneration. Immunogenetic analysis of whole blood obtained at age 68 mo identified the gorilla major histocompatibility class I allele, Gogo-B*0101, which has limited nucleotide sequence similarity to HLA-B27, an allele associated with postinfection reactive arthritis in humans. Sulfasalazine therapy effectively managed reactive arthritis in this gorilla and should be considered for similarly frequently affected animals. Juvenile gorillas, in populations with a history of clinical shigellosis and/or postdiarrhea arthritis, may benefit from prophylactic sulfasalazine therapy after episodes of bacterial enterocolitis. Sulfasalazine therapy should be considered in all gorillas, juvenile and adult, experiencing confirmed Shigella sp.-associated enterocolitis.

AB - A juvenile western lowland gorilla (Gorilla gorilla gorilla) experienced recurrent fever, lethargy, diarrhea, and/or arthritis starting at age 6 mo. During an episode at age 15 mo, Shigella sp. was isolated from diarrheic feces. At age 41 mo, reactive arthritis was diagnosed. In addition, the gorilla's growth was retarded. All arthritic attacks were managed symptomatically prior to age 4 yr, at which time a severe episode precipitated the implementation of therapy with sulfasalazine, an arthritis suppressive medication. Examination 27 mo later revealed cessation of progressive joint pathology although the animal exhibited decreased range of motion in most joints. The gorilla has been on sulfasalazine therapy for 4 yr without lameness. Growth has resumed, and there has been no radiographic evidence of progressive joint degeneration. Immunogenetic analysis of whole blood obtained at age 68 mo identified the gorilla major histocompatibility class I allele, Gogo-B*0101, which has limited nucleotide sequence similarity to HLA-B27, an allele associated with postinfection reactive arthritis in humans. Sulfasalazine therapy effectively managed reactive arthritis in this gorilla and should be considered for similarly frequently affected animals. Juvenile gorillas, in populations with a history of clinical shigellosis and/or postdiarrhea arthritis, may benefit from prophylactic sulfasalazine therapy after episodes of bacterial enterocolitis. Sulfasalazine therapy should be considered in all gorillas, juvenile and adult, experiencing confirmed Shigella sp.-associated enterocolitis.

KW - Gorilla gorilla gorilla

KW - Reactive arthritis

KW - Spondyloarthropathy

KW - Sulfasalazine

KW - Western lowland gorilla

UR - http://www.scopus.com/inward/record.url?scp=0034574339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034574339&partnerID=8YFLogxK

M3 - Article

VL - 31

SP - 539

EP - 551

JO - Journal of Zoo and Wildlife Medicine

JF - Journal of Zoo and Wildlife Medicine

SN - 1042-7260

IS - 4

ER -